A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Clinical trial NCT00283114 · COMPLETED

Trial details

NCT number: NCT00283114
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndrome Myeloproliferative Disorders Chronic Myelomonocytic Leukemia

Start date: 2005-11-01
Primary completion: 2010-01-01
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.